Enhanced Genetic Awareness and Genetic Evaluation for Men Through Technology, ENGAGEMENT Study

Thomas Jefferson University118 enrolled

Overview

This study assesses perceived usefulness of a web-based virtual prostate cancer genetics board for providers across academic, community, and veteran affairs settings to discuss prostate cancer genetics cases, precision treatment, and screening recommendation. Information gained from interviews and surveys of participants taking part in the virtual genetics board may lend insights into perceived usefulness, perceived ease of use, acceptability, self-efficacy, genetics knowledge, and barriers/facilitators to implementation to refine the process.

PRIMARY OBJECTIVE: I. To assess perceived usefulness of a virtual genetics board. SECONDARY OBJECTIVE: I. To assess acceptability/feasibility, perceived ease of use, self-efficacy for recommendations, genetics knowledge. OUTLINE: Participants complete a survey about genetic knowledge and self efficacy and then attend virtual genetics board. After virtual genetics board meeting, participants complete a second survey about perceived usefulness, ease of use, acceptability, feasibility, self-efficacy and genetic knowledge. Participants may also complete a semi-structured interview after virtual genetics board.

Study Type

OBSERVATIONAL

Enrollment

118

Conditions

Prostate Carcinoma

Interventions

Educational InterventionOTHER

Attend virtual genetics board

Survey AdministrationOTHER

Complete survey

InterviewOTHER

Complete interview

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study: * Healthcare providers (medical oncologists, radiation oncologists, urologists, primary care providers, mid-level providers) who evaluate, manage, or treat men with prostate cancer or screen men for prostate cancer. * Providers who perform prostate cancer genetic testing for men (genetic counselors or healthcare providers) * Scientists and researchers * Advocacy or patient stakeholder organization members Exclusion Criteria: • Non-medical providers

Locations (1)

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Mean Likert scaled perceived usefulness scores of the virtual genetics board

Perceived usefulness will be judged against a benchmark mean score of 5/7.

Time frame: After virtual genetics board

Secondary Outcomes

Means or changes in means of Likert scaled acceptability/feasibility

Will be summarized by means, standard deviations, and 95% confidence intervals.

Time frame: Before and after virtual genetics board

Perceived ease of use

Will be summarized by means, standard deviations, and 95% confidence intervals.

Time frame: After virtual genetics board

Self-efficacy for recommendations

Will be summarized by means, standard deviations, and 95% confidence intervals.

Time frame: Before and after virtual genetics board

Change in mean scores on 17 genetics knowledge test questions

Will be summarized by means, standard deviations, and 95% confidence intervals.

Time frame: Baseline up to post-virtual genetics board

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.